Search for: "Myers v. Pfizer, Inc."
Results 61 - 71
of 71
Sorted by Relevance
|
Sort by Date
25 Apr 2015, 11:03 am
The first edition of the Reference Manual on Scientific Evidence [Manual] was published in 1994, a year after the Supreme Court delivered its opinion in Daubert. [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
19 Feb 2021, 2:28 am
This second appeal followed with Bristol Myers Squibb Co., Pfizer Inc., and Eli Lilly and Company, among others, filing dueling amicus briefs. [read post]
9 May 2008, 10:30 pm
: (Afro-IP), (Managing Intellectual Property), Rwanda: Four years after AIDS drugs bill passed, first low cost meds may head to Rwanda: (GenericsWeb), US: Abbott’s first quarter lobbying tab hits $880,000: (Patent Docs), US: House Bill would expand federal drug pedigree requirements and preempt state requirements: (FDA Law Blog), US: Purchasing Canadian drugs and patent infringement: Litecubes decision: (Patently-O), US: Neuralstem seeks to reopen stayed patent case… [read post]
13 Apr 2014, 8:59 am
Bristol-Myers Squibb Co. v. [read post]
28 Oct 2011, 7:00 am
Pfizer, Inc., 358 F.3d 659, 661 (9th Cir. 2004) (“the doctor who prescribed [the drug] . . . failed to read [the defendant’s] published warnings before prescribing the drug. [read post]
20 Jun 2008, 8:07 am
: (IP finance), Technical assistance a key point of discussion at TRIPS Council: (Intellectual Property Watch), WIPO turmoil as new DG’s future comes under threat: (IAM), WIPO to host inter-regional forum to explore strategies to enhance development and service-orientation of IP offices: (WIPO), Controversy over lack of transparency and overreaching enforcement provisions in ACTA: (Spicy IP), (Spicy IP) Global - Trade Marks / Domain Names / Brands World anti-counterfeiting day:… [read post]
13 May 2012, 4:46 pm
Hospira, Inc. [read post]
16 Aug 2008, 2:43 am
– discussion of Washington Post article on Ismed’s efforts to promote follow-on biologics approval pathway: (Patent Baristas), (Patent Docs), US: Congressional fact-finding on follow-on biologics: (Patent Docs), US: David v Monsanto: Biotechnology patent ‘exhaustion’ after Quanta, Supreme Court petition: (Hal Wegner), US: Ulysses Pharmaceuticals announces issuance of patent for novel class of ant [read post]
2 May 2008, 7:00 am
: Lupin v Abbott Labs: (FDA Law Blog), Plavix (Clopidogrel) – US: Apotex sues FDA to recover 180-day exclusivity on generic Plavix: (Orange Book Blog), Plavix (Clopidogrel) – US: Former Bristol-Myers Squibb executive charged over lying about Plavix deal struck with rival Apotex: (Managing Intellectual Property), Risperdal (Resperidone) – US: Apotex files motion to intervene in relisting of Risperdal patent case; Teva quickly files… [read post]
11 Apr 2008, 9:00 am
No problem…: Lundbeck A/S v Generics UK Ltd & Ors: (IPKat), Exelon (Rivastigmine Tartrate) – Dr Reddy’s and Novartis settle Exelon patent dispute: (Therapeutics Daily), GeneMaker – Codon Devices, Blue Heron Biotechnology settle patent suit over gene synthesis platform: (Patent Docs), Glucophage (Metformin) – Depomed settles patent litigation against IVAX: (SmartBrief), (IP Law360), (GenericsWeb), Lexapro… [read post]
